Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Markets Regulatory Tracker: Brazil, China (Vol. 4 No. 20)

This article was originally published in PharmAsia News

Executive Summary

Brazil’s Senate seeks an increase in clinical drug trials while Abbott Laboratires voluntarily recalls a blood glucose meter in China on concerns of possible erroneous results.

You may also be interested in...



Emerging Markets Regulatory Tracker: India Plans Regulatory Overhaul

India’s health ministry has laid out basic steps towards an overhaul of drug regulation at the local level, identifying a number of areas of concern.

Emerging Markets Regulatory Tracker: China Self-Audit Results Released

China has released the results of back on proposed standards for the accreditation of clinical trial committees, investigators and sites.

Emerging Markets Regulatory Tracker: China Device Classifications

China has finalized revised rules for the classification of medical devices, which will come into effect from the start of next year.

Topics

Related Companies

UsernamePublicRestriction

Register

OM004514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel